In support of this hypothesis, in our previous studies, we have demonstrated that loss of ERα results in the upregulation of p53-target genes and that ERα antagonizes p53′s transactivation function in breast cancer cells [102, 103]. The gene discussed is TP53; the disease is breast carcinoma.